Mesoblast Stock Fundamentals
MEOBF Stock | USD 0.19 0.00 0.00% |
Mesoblast fundamentals help investors to digest information that contributes to Mesoblast's financial success or failures. It also enables traders to predict the movement of Mesoblast Pink Sheet. The fundamental analysis module provides a way to measure Mesoblast's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mesoblast pink sheet.
Mesoblast |
Mesoblast EBITDA Analysis
Mesoblast's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Mesoblast EBITDA | (70.3 M) |
Most of Mesoblast's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mesoblast is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition |
According to the company disclosure, Mesoblast reported earnings before interest,tax, depreciation and amortization of (70.3 Million). This is 108.01% lower than that of the Healthcare sector and 170.19% lower than that of the Biotechnology industry. The ebitda for all United States stocks is 101.8% higher than that of the company.
Mesoblast Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mesoblast's current stock value. Our valuation model uses many indicators to compare Mesoblast value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mesoblast competition to find correlations between indicators driving Mesoblast's intrinsic value. More Info.Mesoblast is considered to be number one stock in total asset category among related companies. It is considered to be number one stock in working capital category among related companies reporting about 0.06 of Working Capital per Total Asset. The ratio of Total Asset to Working Capital for Mesoblast is roughly 16.55 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Mesoblast by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Mesoblast's Pink Sheet . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mesoblast's earnings, one of the primary drivers of an investment's value.Mesoblast Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mesoblast's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Mesoblast could also be used in its relative valuation, which is a method of valuing Mesoblast by comparing valuation metrics of similar companies.Mesoblast is currently under evaluation in return on asset category among related companies.
Mesoblast Fundamentals
Return On Equity | -0.16 | |||
Return On Asset | -0.0688 | |||
Operating Margin | (9.53) % | |||
Current Valuation | 504.31 M | |||
Shares Outstanding | 736.58 M | |||
Shares Owned By Insiders | 11.76 % | |||
Shares Owned By Institutions | 26.13 % | |||
Price To Earning | (6.34) X | |||
Price To Book | 0.92 X | |||
Price To Sales | 68.10 X | |||
Revenue | 10.21 M | |||
Gross Profit | (53.36 M) | |||
EBITDA | (70.3 M) | |||
Net Income | (91.35 M) | |||
Cash And Equivalents | 60.45 M | |||
Cash Per Share | 0.08 X | |||
Total Debt | 91.62 M | |||
Debt To Equity | 0.21 % | |||
Current Ratio | 1.36 X | |||
Book Value Per Share | 0.71 X | |||
Cash Flow From Operations | (65.78 M) | |||
Earnings Per Share | (0.14) X | |||
Number Of Employees | 77 | |||
Beta | 2.43 | |||
Market Capitalization | 544.31 M | |||
Total Asset | 662.14 M | |||
Retained Earnings | (288 M) | |||
Working Capital | 40 M | |||
Current Asset | 71 M | |||
Current Liabilities | 31 M | |||
Z Score | 3.0 | |||
Net Asset | 662.14 M |
About Mesoblast Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mesoblast's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mesoblast using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mesoblast based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 77 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Mesoblast in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Mesoblast's short interest history, or implied volatility extrapolated from Mesoblast options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Mesoblast Piotroski F Score and Mesoblast Altman Z Score analysis. For more detail on how to invest in Mesoblast Pink Sheet please use our How to Invest in Mesoblast guide.Note that the Mesoblast information on this page should be used as a complementary analysis to other Mesoblast's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Mesoblast Pink Sheet analysis
When running Mesoblast's price analysis, check to measure Mesoblast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mesoblast is operating at the current time. Most of Mesoblast's value examination focuses on studying past and present price action to predict the probability of Mesoblast's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mesoblast's price. Additionally, you may evaluate how the addition of Mesoblast to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Transaction History View history of all your transactions and understand their impact on performance | |
Fundamental Analysis View fundamental data based on most recent published financial statements |